期刊文献+

辛伐他汀对PTHrP诱导的破骨细胞性骨吸收及小鼠颅盖骨代谢的影响 被引量:5

Effect of simvastatin on the osteoclastic resorption stimulated by PTHrP and anabolism with murine calvarial organ culture in vitro
下载PDF
导出
摘要 [目的]探讨辛伐他汀对体外甲状旁腺素相关肽(PTHrP)诱导小鼠的破骨细胞骨吸收功能的作用及其小鼠骨代谢的影响。[方法]采用PTHrP诱导小鼠骨髓细胞培养破骨细胞和小鼠颅盖骨培养体系,检测辛伐他汀作用8 d后破骨细胞骨吸收陷窝和培养上清钙的变化;检测小鼠颅盖骨培养上清碱性磷酸酶和钙含量,组织学观察小鼠颅盖骨形态学变化。[结果]辛伐他汀体外可明显抑制PTHrP诱导小鼠的破骨细胞骨吸收陷窝的形成及培养上清钙的释放,辛伐他汀体外可增强小鼠颅盖骨培养上清碱性磷酸酶的活性,组织学观察到辛伐他汀使小鼠颅盖骨矿化增强。[结论]辛伐他汀体外不仅可促进小鼠颅盖骨的成骨活性,并且可明显抑制PTHrP诱导小鼠的破骨细胞骨吸收功能,对骨吸收性疾病有着重要的防治作用。 [ Objective] To study the effect of simvastatin in the osteoclastic resorption stimulated by PTHrP and murine bone anabolism in vitro. [ Method ] The bone resorption activities of the osteoclast stimulated by PTHrP were evaluated after treatment with simvastatin for 8 days in vitro; the concentration of Ca^2+ in the supematant was also detected by atomic absorption spectrometer. The concentration of ALP and Ca^2+ of the supematant in murine calvarial organ culture were detected. The histology of ealvaria was observed. [ Result] Simvastatin greatly inhibited the osteoclastic bone resorption stimulated by PTHrP in vitro and reduced the release of Ca^2 +. Simvastatin increased the ALP activities and bone mineralization of murines calvarial organ culture in vitro. [Condusion] Simvastatin may inhibit the osteoclasric resorption stimulated by PTHrP and promote osteoblast differentiation and bone mineralization in vitro, thus play an important role in the prevention and treatment of osteoporosis.
出处 《中国矫形外科杂志》 CAS CSCD 北大核心 2006年第9期683-686,共4页 Orthopedic Journal of China
关键词 辛伐他汀 破骨细胞 骨吸收 甲状旁腺素相关肽(PTHrP) Simvastatin Osteoclast Bone resorption PTHrP
  • 相关文献

参考文献11

  • 1Mundy GR, Oarrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins [J]. Science, 1999,286 ( 5446 ) : 1946-1949.
  • 2Vander Horst O,Van Bezooijen RL,Deckers MM ,et al. Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation[J]. Bone,2002,31:661-669.
  • 3Wang EA,Israel DI,Kelly S,et al. Bone morphogenetic protein-2 causes commitmem and differentiation in C3H10T1/2 and 3T3 cells[J].Growth Factors, 1993,9:57-71.
  • 4Martin TJ. Humoral hypercalcemia of maliganacy [J]. Bone Miner,1988,4:83-89.
  • 5Mundy GR. Hypercalcemia of maliganacy revisited [J]. J Clin Invest,1988,82:1-6.
  • 6陶惠人,王全平,李寰.甲状旁腺素相关肽诱导骨髓细胞生成破骨细胞及对骨吸收的影响[J].中国临床康复,2004,8(17):3250-3251. 被引量:6
  • 7许多荣,余学清,方荸荠.甲状旁腺激素在体外对破骨细胞分化及骨重吸收能力的影响[J].中华肾脏病杂志,2005,21(4):186-190. 被引量:14
  • 8Coxon FP, Helffich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and Survival: inhibition by bisphosphonates and GGTI-298 [J]. J Bone Miner Res, 2000,15 :1467-1476.
  • 9Grasser WA, Baumann AP, Petras SF, et al. Regulation of osteoclast differentiation by statins[J]. J Musculoskelet Neuronal Interact,2003,3(1):53-62.
  • 10Yon Knoch F,Wedmeyer C, Heckdei A,et al. A comparison of the antiresorption effects of bisphosphonates and statins on polyethylene particle-induced osteilysis[J]. Biomed Tech ( Berl), 2005,50(6):195-200.

二级参考文献35

  • 1陶惠人,王全平,名井阳,吉川秀树.甲状旁腺素相关肽诱导的局部骨吸收及高钙血症动物模型特点[J].中华创伤骨科杂志,2004,6(10):1140-1143. 被引量:6
  • 2刘波,于世凤,庞淑珍.新伐他汀体外对破骨细胞性骨吸收及大鼠骨代谢的影响[J].中国骨质疏松杂志,2005,11(3):351-355. 被引量:13
  • 3Fong AM, Erickson HP, Zachariah JP, et al. Ultrastructure and function of the fractalkine mucin domain in CX3C chemokine domain presentation. J Biol Chem, 2000,75: 3781-3786.
  • 4Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the members of the tumor necrosis factor receptor and ligand fanilies. Endocr Res, 1999,20: 345-357.
  • 5Duorong Xu,Zhenqi Shi,Xu Feng,et al. Development of a chimacric receptor approach to study signaling by tumour necrosis factor family members. Biochem J, 2004,383:219-225.
  • 6Wei L, Duorong X, Hongmei Y, et al. Functional identification of three RANK cytoplasmic motif mediating osteoclast differentiation and function. J Biol Chem, 2004,279:54759-54769.
  • 7Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteogenesisinhibitory factor and is identical to TRANCE/RANKL.Proc Natl Acad Sci UAS, 1998,95:3597-3602.
  • 8Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the members of the tumor necrosis factor receptor and ligand families. Endocr Res, 1999,20: 345-357.
  • 9Hofbauer L, Khosla S, Dunstan C, et al. The roles of osteoprotegerin and osteoprogerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res,2000, 15:2-12.
  • 10Shi W, Michael WH, Steven L, et al. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and Mitogen-activated protein kinase signaling. J Biol Chem,2002,277: 6622-6630.

共引文献17

同被引文献73

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部